CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project explores the role of retinoic acid signaling in acute myeloid leukemia, particularly how it affects cell differentiation and self-renewal. It aims to identify mechanisms and potential drug combinations that could improve treatment outcomes for patients with this type of cancer.
In acute promyelocytic leukaemia (APL), retinoic acid (RA) and arsenic trioxide (ATO) bind the PML/RARA fusion to promote its degradation, derepressing unknown master regulatory genes and activating a PML/P53 checkpoint which is required for APL cure. APL initiation deregulates Retinoic Acid Receptor a (RARA) signalling.
These deregulations are likely shared with a sizable subset of non-APL acute myeloid leukaemia (AML): the 30% that overexpress normal RARA and exhibit some RA-sensitivity ex viv…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
